Simulations Using a Drug-Disease Modeling Framework and Phase II Data Predict Phase III Survival Outcome in First-Line Non-Small-Cell Lung Cancer

Simulations were performed for carboplatin/paclitaxel (C/P) plus motesanib or bevacizumab vs. C/P as first-line treatment for advanced non small-cell lung cancer (NSCLC) using a published drug disease model. With 700 patients in each arm, simulated hazard ratios for motesanib (0.87; 95% confidence interval [CI], 0.71-1.1) and bevacizumab (0.89; 95% CI, 0.73-1.1) agreed with results from […]

Read More
Learn More